EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Dynamic programmed death-ligand 1 and multimodal biomarkers in gastric cancer immunotherapy

Abdellatif Bouayad

World Journal of Gastrointestinal Oncology · 2026-11-15 · 18 (11)

DOI: 10.4251/wjgo.120353 ↗
AbstractBibliografische Angaben

Abstract

Immune checkpoint inhibitors targeting programmed death-ligand 1 (PD-L1) and programmed death-1 (PD-1) are promising therapies for advanced gastric cancer (GC). However, challenges remain in identifying the best biomarkers to guide anti-PD-L1/PD-1 therapy. There are two competing paradigms for selecting immunotherapy biomarkers in clinical practice. One favors static biomarkers, such as Epstein-Barr virus positivity, microsatellite instability status, and the PD-L1 combined positive score, due to their track record in clinical trials. The other emerging view prefers dynamic tumor biomarkers, such as circulating tumor DNA, exosomal PD-L1, and immune cell profiling, to better reveal therapy-induced immune changes. This article discusses three main questions for real-time assessment of anti-PD-L1/PD-1 therapy in advanced GC: (1) What complementary approaches can overcome static PD-L1 assessment limitations; (2) How dynamic tumor biomarkers could be used in clinical practice to improve monitoring and patient selection; and (3) How multimodal artificial intelligence could support personalized immunotherapy. These strategies may improve patient selection and enhance the clinical impact of immunotherapy in advanced GC.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →